Form 4: NeuroPace CFO Patrick Williams Receives Significant Equity Grant

NeuroPace Inc.'s Chief Financial Officer, Patrick F. Williams, was granted 51,850 restricted stock units and options to purchase 87,950 shares of common stock, aligning his interests with shareholders.

Summary

• Patrick F. Williams, Chief Financial Officer of NeuroPace Inc. (NPCE), acquired 51,850 shares of common stock in the form of Restricted Stock Units (RSUs) on June 20, 2025.
• Each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement, with no purchase price.
• The RSUs will vest 25% on June 20, 2026, and the remaining RSUs will vest in twelve equal quarterly installments thereafter.
• Mr. Williams also acquired options to buy 87,950 shares of common stock on June 20, 2025, with an exercise price of $10.41 per share.
• These stock options will vest 25% on June 20, 2026, with the remaining shares vesting in twelve equal quarterly installments thereafter.
• The stock options have an expiration date of June 19, 2035.

Sentiment

Score: 7

Explanation: The grant of significant equity to a key executive like the CFO is generally viewed positively as it aligns management's interests with shareholders and incentivizes long-term performance. It's a standard compensation practice.

Positives

• The significant equity grant to the Chief Financial Officer aligns management's financial interests directly with those of the shareholders, incentivizing long-term performance.
• The vesting schedule for both RSUs and stock options encourages long-term retention of a key executive.

Future Outlook

The document details future vesting schedules for the granted equity, with initial vesting for both RSUs and stock options set for June 20, 2026, followed by quarterly installments.

Industry Context

This Form 4 filing is a standard disclosure of executive compensation in the form of equity grants, a common practice across the biotechnology and medical device industries to attract and retain talent and align executive interests with shareholder value.

Related Party Transactions

• Patrick F. Williams, the Chief Financial Officer, received an equity grant consisting of 51,850 Restricted Stock Units and options to purchase 87,950 shares of common stock from NeuroPace Inc. This constitutes a transaction between the company and a key executive.

Stakeholder Impact

• Shareholders: The equity grant aligns the CFO's financial incentives with shareholder value creation, potentially leading to improved long-term company performance.
• Employees: While not directly impacting all employees, executive compensation practices can influence overall company culture and compensation strategies.
• CFO (Patrick F. Williams): Receives significant long-term equity compensation, providing a strong incentive for continued dedication and performance.

Next Steps

• Vesting of 25% of the Restricted Stock Units on June 20, 2026.
• Vesting of 25% of the Stock Options on June 20, 2026.
• Subsequent quarterly vesting of the remaining RSUs and Stock Options over twelve installments.

Key Dates

Keywords

NeuroPace, NPCE, SEC Form 4, Insider Transaction, Equity Grant, Restricted Stock Units, Stock Options, CFO Compensation, Executive Compensation